CEUs available for live webinar attendance only!
Interested in attending additional sessions in this series? Use the buttons below to learn more and register.
Cancer‑associated thrombosis (CAT) is a serious complication that affects outcomes for patients all too often.
On March 3, Stephanie Carlin will provide a comprehensive overview of CAT, giving pharmacy teams evidence‑based insights to make more confident, informed decisions for this high‑risk population.
By the end of this session, participants will be able to:
— Discuss the epidemiology of cancer-associated thrombosis (CAT)
— Describe patient, disease and medication-related risk factors for CAT
— Differentiate treatment options for CAT: Direct Oral Anticoagulants (DOACs) vs Low Molecular Weight Heparin (LMWH)
— Discuss use of anticoagulation in special populations in CAT (e.g. renal impairment, drug interactions)
About Stephanie Carlin, BScPhm, PharmD, ACPR2 (Thrombosis)
Stephanie Carlin is a Thrombosis Pharmacist at Hamilton Health Sciences and Assistant Professor in the Division of Hematology and Thromboembolism in the Department of Medicine at McMaster University. She completed a Bachelor of Science at the University of Toronto, followed by a Doctor of Pharmacy at the University of Florida. She completed two pharmacy residency programs, a PGY1 at Hamilton Health Sciences, followed by a PGY2 at Sunnybrook Health Sciences Centre in Thrombosis. In addition to her clinical and teaching activities, she is actively involved in thrombosis research with an interest in anticoagulation in special populations, specifically patients with mechanical valves, liver disease, and drug interactions. She is a member of Thrombosis Canada and regularly contributes to the writing and updating of clinical guides. She co-chairs the International Society of Thrombosis and Hemostasis Subcommittee on Hemostatic Management of Patients with Liver Disease.